Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.19% | -149.04% | -44.00% | -316.05% | -28.57% |
| Total Depreciation and Amortization | 473.33% | 0.00% | 214.29% | 114.29% | -84.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -123.88% | 602.52% | -69.12% | -85.74% | -6.74% |
| Change in Net Operating Assets | -190.67% | -17.25% | 90.45% | -193.66% | 36.32% |
| Cash from Operations | -201.13% | -7.64% | -43.33% | -501.18% | -123.90% |
| Capital Expenditure | 100.00% | 100.00% | 44.23% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.54% | -- | -- | -- | -- |
| Cash from Investing | 35.54% | 173,180.00% | 33,169.23% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,515.71% | -- | -99.95% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 408.49% | -- | -- | -- | -310.20% |
| Cash from Financing | 8,667.32% | 110.76% | -99.97% | -- | -8,438.46% |
| Foreign Exchange rate Adjustments | 126.13% | -97.30% | 100.50% | 13,846.67% | -1,910.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 249.91% | 399.43% | -107.05% | -947.34% | -1,734.76% |
